AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Currently, there is a lack of high-quality clinical evidence for subsequent treatment options for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) after first-line treatment, especially for subsequent treatment after first-line therapy combined with PD-1 inhibitors. Increasing evidence suggests that low-dose radiation (LDRT) can reshape the tumor microenvironment.Cadonilimab is a bispecific antibody that specifically binds to CTLA-4 and PD-1 proteins in the human body. Considering that low-dose radiotherapy and cadonilimab both have immunomodulatory effects, this study inten

Trial Details

NCT ID
NCT06494995
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Cadonilimab
  • Low-dose radiotherapy
  • SBRT
  • Capecitabine
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients who signed the informed consent and were willing to complete the study according to the protocol;
  • Aged ≥18 years and ≤75 years;
  • Histologically confirmed head and neck squamous cell carcinoma or nasopharyngeal carcinoma;
  • Patients with recurrent and metastatic head and neck squamous cell carcinoma or nasopharyngeal carcinoma, with progression on first-line treatment …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →